Compare Neurocrine Biosciences Inc (NBIX) vs SAP SE (SAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs SAP SE — how do they compare? Neurocrine Biosciences Inc trades at $152.5 (market cap $16.46B), while SAP SE trades at $203.99 (market cap $240.81B). The key difference: SAP SE is far larger — about 14.6× Neurocrine Biosciences Inc's market cap, and SAP SE pays a 1.4% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | SAP | |
|---|---|---|
Market Cap | $16.46B | $240.81B |
Sector | Health | Technology |
52-Week High | $185.50 | $280.46 |
52-Week Low | $123.10 | $146.38 |
Enterprise Value | $16.48B | $239.52B |
Dividend Yield | — | 1.4% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About SAP SE
Founded in 1972 by former IBM employees, SAP provides database technology and enterprise resource planning software to enterprises around the world. Across more than 180 countries, the company serves 440,000 customers, approximately 80% of which are small to medium-size enterprises.
Read more on SAP →
